{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:18:52Z","timestamp":1783354732761,"version":"3.54.6"},"reference-count":40,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["201038"],"award-info":[{"award-number":["201038"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,12,7]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Real-world evidence concerning the cardiovascular (CV) risk of umeclidinium (UMEC) monotherapy or UMEC\/vilanterol (VI) is scarce. This real-world study investigated CV risk in new users of UMEC or UMEC\/VI\n                      <jats:italic>versus<\/jats:italic>\n                      new users of tiotropium (TIO) in patients with chronic obstructive pulmonary disease (COPD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, observational, multinational, cohort study enrolled patients \u226518\u2005years with COPD who initiated UMEC, UMEC\/VI or TIO between 2 February 2016 and 31 January 2023. Noninferiority (95% confidence interval upper bound &lt;2.0) of UMEC and UMEC\/VI to TIO was compared for the time-to-first event (hazard ratio (HR) over 24\u2005months) of a composite CV end-point of myocardial infarction, stroke, heart failure or sudden cardiac death. Stabilised inverse probability of treatment weighting adjusted for differences in baseline covariate balance between groups. Incidence rates for the composite CV end-point were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 6606 patients were enrolled; 6165 were included in the analysis. Both UMEC (n=1246) and UMEC\/VI (n=2448) were noninferior to TIO (n=2471) for the risk of the composite CV end-point (adjusted HR (95% CI): UMEC\n                      <jats:italic>versus<\/jats:italic>\n                      TIO: 1.254 (0.830\u20131.896); UMEC\/VI\n                      <jats:italic>versus<\/jats:italic>\n                      TIO: 1.352 (0.952\u20131.922)). Unadjusted composite CV incidence rates were low across cohorts (incidence rate (95% CI) per 100 person-years: UMEC: 1.157 (0.814\u20131.594); UMEC\/VI: 1.287 (1.034\u20131.584); TIO: 0.924 (0.716\u20131.174)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both UMEC and UMEC\/VI were noninferior to TIO for composite CV risk, suggesting that physicians may consider escalating patients to dual bronchodilator therapy if COPD symptoms are not effectively managed with monotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01691-2025","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:55:25Z","timestamp":1771268125000},"page":"01691-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular events in patients with COPD after long-acting bronchodilator initiation"],"prefix":"10.1183","volume":"12","author":[{"given":"Dave","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Newby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Jonsson Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Roman-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-4820","authenticated-orcid":false,"given":"Peter","family":"Kardos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Donald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026070608551436000_12.3.01691-2025.1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Date last accessed: 6 February 2025. Date last updated: 15 November 2024. https:\/\/goldcopd.org\/wp-content\/uploads\/2024\/11\/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf"},{"key":"2026070608551436000_12.3.01691-2025.2","first-page":"197","article-title":"Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies","volume":"5","author":"Bateman","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551436000_12.3.01691-2025.3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/COPD.S4802","article-title":"Tiotropium HandiHaler in the treatment of COPD: a safety review","volume":"4","author":"Kesten","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551436000_12.3.01691-2025.4","unstructured":"Boehringer Ingelheim . Spiriva RESPIMAT prescribing information. Date last accessed: 28 October 2024. Date last updated: January 2025. https:\/\/content.boehringer-ingelheim.com\/DAM\/68a8a6b5-4e9a-4508-85d3-af1e01205009\/spiriva%20respimat-us-pi.pdf"},{"key":"2026070608551436000_12.3.01691-2025.5","unstructured":"GSK . Incruse ELLIPTA prescribing information. Date last accessed: 28 October 2024. Date last updated: December 2023. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Incruse_Ellipta\/pdf\/INCRUSE-ELLIPTA-PI-PIL-IFU.PDF"},{"key":"2026070608551436000_12.3.01691-2025.6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2040622317700822","article-title":"Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy","volume":"8","author":"Babu","year":"2017","journal-title":"Ther Adv Chronic Dis"},{"key":"2026070608551436000_12.3.01691-2025.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00033213"},{"key":"2026070608551436000_12.3.01691-2025.8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1185\/03007995.2016.1140029","article-title":"Long-term (52\u2005weeks) safety and tolerability of umeclidinium in Japanese patients with chronic obstructive pulmonary disease","volume":"32","author":"Yamagata","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2026070608551436000_12.3.01691-2025.9","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1007\/s12325-021-01855-y","article-title":"Efficacy and safety of umeclidinium\/vilanterol in current and former smokers with COPD: a prespecified analysis of the EMAX trial","volume":"38","author":"Bjermer","year":"2021","journal-title":"Adv Ther"},{"key":"2026070608551436000_12.3.01691-2025.10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2147\/COPD.S407238","article-title":"Clinical and functional effects of inhaled dual therapy umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease: a real-life study","volume":"18","author":"Pelaia","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551436000_12.3.01691-2025.11","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-001931"},{"key":"2026070608551436000_12.3.01691-2025.12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02135-2022"},{"key":"2026070608551436000_12.3.01691-2025.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00302-2022"},{"key":"2026070608551436000_12.3.01691-2025.14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/15412555.2014.974734","article-title":"Prevalence of co-morbidities and severity of COPD","volume":"12","author":"Battaglia","year":"2015","journal-title":"COPD"},{"key":"2026070608551436000_12.3.01691-2025.15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2847"},{"key":"2026070608551436000_12.3.01691-2025.16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12931-020-01407-y","article-title":"Tiotropium in chronic obstructive pulmonary disease \u2013 a review of clinical development","volume":"21","author":"Anzueto","year":"2020","journal-title":"Respir Res"},{"key":"2026070608551436000_12.3.01691-2025.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208606"},{"key":"2026070608551436000_12.3.01691-2025.18","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Date last accessed: 7 February 2025. Date last updated: 14 November 2018. https:\/\/goldcopd.org\/wp-content\/uploads\/2018\/11\/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf"},{"key":"2026070608551436000_12.3.01691-2025.19","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Date last accessed: 7 February 2025. Date last updated 17 February 2023. https:\/\/goldcopd.org\/wp-content\/uploads\/2023\/03\/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf"},{"key":"2026070608551436000_12.3.01691-2025.20","doi-asserted-by":"publisher","DOI":"10.2307\/2531021"},{"key":"2026070608551436000_12.3.01691-2025.21","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"2026070608551436000_12.3.01691-2025.22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1164\/rccm.201901-0061ED","article-title":"On trapped air and trapped blood in chronic obstructive pulmonary disease","volume":"199","author":"Watz","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026070608551436000_12.3.01691-2025.23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2213-2600(18)30054-7","article-title":"Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial","volume":"6","author":"Hohlfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026070608551436000_12.3.01691-2025.24","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s12325-024-02855-4","article-title":"Implications of cardiopulmonary risk for the management of COPD: a narrative review","volume":"41","author":"Singh","year":"2024","journal-title":"Adv Ther"},{"key":"2026070608551436000_12.3.01691-2025.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000840"},{"key":"2026070608551436000_12.3.01691-2025.26","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/COPD.S246348","article-title":"Absence of adverse effects of tiotropium\/olodaterol compared with the monocomponents on long-term heart rate and blood pressure in patients with moderate-to-very-severe COPD","volume":"15","author":"Andreas","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551436000_12.3.01691-2025.27","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2147\/COPD.S246350","article-title":"No influence on cardiac arrhythmia or heart rate from long-term treatment with tiotropium\/olodaterol versus monocomponents by Holter ECG analysis in patients with moderate-to-very-severe COPD","volume":"15","author":"Andreas","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551436000_12.3.01691-2025.28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00408-024-00677-3","article-title":"Cardiovascular events with the use of long-acting muscarinic receptor antagonists: an analysis of the FAERS database 2020\u20132023","volume":"202","author":"Matera","year":"2024","journal-title":"Lung"},{"key":"2026070608551436000_12.3.01691-2025.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.02.646"},{"key":"2026070608551436000_12.3.01691-2025.30","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.2147\/COPD.S146338","article-title":"The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis","volume":"12","author":"Rogliani","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551436000_12.3.01691-2025.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2239OC"},{"key":"2026070608551436000_12.3.01691-2025.32","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","article-title":"Assessing short-term deterioration in maintenance-na\u00efve patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials","volume":"33","author":"Maleki-Yazdi","year":"2016","journal-title":"Adv Ther"},{"key":"2026070608551436000_12.3.01691-2025.33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2147\/COPD.S119032","article-title":"Umeclidinium\/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study","volume":"12","author":"Kerwin","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551436000_12.3.01691-2025.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.10.002"},{"key":"2026070608551436000_12.3.01691-2025.35","first-page":"538","article-title":"Beyond access: factors associated with spirometry underutilization among patients with a diagnosis of COPD in urban tertiary care centers","volume":"9","author":"Baldomero","year":"2022","journal-title":"Chronic Obstr Pulm Dis"},{"key":"2026070608551436000_12.3.01691-2025.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2015.82"},{"key":"2026070608551436000_12.3.01691-2025.37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5334\/aogh.2713","article-title":"Cardiovascular diseases in central and eastern Europe: a call for more surveillance and evidence-based health promotion","volume":"86","author":"Movsisyan","year":"2020","journal-title":"Ann Glob Health"},{"key":"2026070608551436000_12.3.01691-2025.38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","article-title":"Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial","volume":"20","author":"Maltais","year":"2019","journal-title":"Respir Res"},{"key":"2026070608551436000_12.3.01691-2025.39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200602-244OC"},{"key":"2026070608551436000_12.3.01691-2025.40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir Med"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01691-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:56:00Z","timestamp":1783353360000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01691-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1183\/23120541.01691-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01691-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}